NASDAQ: ABOS - Acumen Pharmaceuticals, Inc.

Yield per half year: -7.35%
Sector: Healthcare

Share chart Acumen Pharmaceuticals, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About

Acumen Pharmaceuticals, Inc., биофармацевтическая компания клинической стадии, занимается разработкой терапевтических средств для лечения болезни Альцгеймера и других нейродегенеративных заболеваний. Компания сосредоточена на продвижении препарата-кандидата для таргетной иммунотерапии ACU193, который находится на клинической стадии фазы I для нацеливания на растворимые олигомеры бета-амилоида. Компания Acumen Pharmaceuticals, Inc. была зарегистрирована в 1996 году и базируется в Шарлоттсвилле, штат Вирджиния.

Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

P/S 187.43
P/BV 1.2
EV/EBITDA 0.8556
Цена ао 2.9
EBITDA -0.0077
Сайт https://acumenpharm.com
Выручка 0.0017
Див.доход ао 0
P/E 4.4
ISIN US00509G2093
Число акций ао 0.04861 млрд
Валюта usd
IPO date 2021-07-01
Sector Health Care
Industry Biotechnology
Валюта отчета usd
Change price per day: +1.4% (2.86)
Change price per week: +28.89% (2.25)
Change price per month: +16.94% (2.48)
Change price per 3 month: +1.05% (2.87)
Change price per half year: -7.35% (3.13)
Change price per year: -16.91% (3.49)
Change price per 3 year: -79.89% (14.42)
Change price per year to date: +28.89% (2.25)
All parameters

Underestimation

Title Value Grade
P/S 703.62 1
P/BV 0.6737 10
P/E 4.4 10
EV/EBITDA -2.32 0
Total: 5.13

Efficiency

Title Value Grade
ROA, % -16.89 0
ROE, % -19.62 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.4627 10
Total: 7.8

Growth impulse

Title Value Grade
Yield Revenue, % -30 0
Yield Ebitda, % 672.44 10
Yield EPS, % 299.03 10
Total: 8
More

Institutions Volume Share, %
Alyeska Investment Group, L.P. 940 1.56
Sands Capital Ventures, LLC 3 5.69
Franklin Resources, Inc. 3 5.65
Millennium Management LLC 3 4.38
Rock Springs Capital Management, LP 2 3.83
FMR, LLC 2 3.48
Laurion Capital Management, LP 2 3.15
Vanguard Group Inc 2 2.77
Knollwood Investment Advisory, LLC 2 2.71
Price (T.Rowe) Associates Inc 1 1.83

ETF Share, % Profitability for 1 year, % Dividends, %
Avantis U.S Small Cap Equity ETF 0.01048 35.517080018718 1.68271
ProShares Hedge Replication ETF 0.00062 6.8665973306333 1.47892
iShares Neuroscience and Healthcare ETF 0.2104 20.843202273804 0.03
iShares Micro-Cap ETF 0.02657 43.316995205115 1.54048
ProShares UltraPro Russell2000 0.00227 125.96465921385 1.47873
Vanguard Russell 3000 ETF 0 38.467141890837 1.43817
Vanguard Russell 2000 ETF 0 41.410408042578 1.48801



Head Job title Payment Year of birth
Mr. Matt Zuga CFO & Chief Business Officer 608.29k
Mr. Russell Barton M.S. Chief Operating Officer 223.68k 1959 (65 years)
Mr. Derek M. Meisner Esq., J.D. Chief Legal Officer & Corporate Secretary 240.17k 1971 (53 years)
Ms. Alex Braun M.B.A. VP & Head of Investor Relations N/A
Dr. Grant A. Krafft Ph.D. Co-Founder 42k
Dr. Caleb E. Finch Ph.D. Co-Founder N/A
Dr. William L. Klein Ph.D. Co-Founder N/A
Ms. Kelly Carranza Vice President, Finance & Accounting and Corporate Controller N/A
Dr. James Doherty Ph.D. President & Chief Development Officer N/A 1968 (56 years)
Mr. Daniel J. O'Connell M.B.A. CEO & Director 1970 (54 years)

Address: United States, Charlottesville. VA, 427 Park Street - open in Google maps, open in Yandex maps
Website: https://acumenpharm.com